WO1998012175A1 - Derives de prostaglandine fluores et medicaments - Google Patents
Derives de prostaglandine fluores et medicaments Download PDFInfo
- Publication number
- WO1998012175A1 WO1998012175A1 PCT/JP1997/003236 JP9703236W WO9812175A1 WO 1998012175 A1 WO1998012175 A1 WO 1998012175A1 JP 9703236 W JP9703236 W JP 9703236W WO 9812175 A1 WO9812175 A1 WO 9812175A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- fluoro
- unsubstituted
- dokishi
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 87
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 title abstract description 11
- -1 vinylene, ethylene, ethynylene Chemical group 0.000 claims abstract description 252
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 59
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 24
- 125000002252 acyl group Chemical group 0.000 claims abstract description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 21
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 20
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 208000030533 eye disease Diseases 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 51
- 125000004432 carbon atom Chemical group C* 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 239000011737 fluorine Substances 0.000 claims description 17
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 15
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 206010030043 Ocular hypertension Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000000144 pharmacologic effect Effects 0.000 abstract description 8
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 229940069417 doxy Drugs 0.000 description 62
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 50
- 150000004702 methyl esters Chemical class 0.000 description 45
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 35
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 35
- 239000000203 mixture Substances 0.000 description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
- 238000000034 method Methods 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000003682 fluorination reaction Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 17
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 16
- 230000004410 intraocular pressure Effects 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 14
- 125000000962 organic group Chemical group 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 125000004494 ethyl ester group Chemical group 0.000 description 13
- 210000001508 eye Anatomy 0.000 description 13
- 150000002430 hydrocarbons Chemical class 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 229940126062 Compound A Drugs 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000005604 Prosulfuron Substances 0.000 description 11
- LTUNNEGNEKBSEH-UHFFFAOYSA-N Prosulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)CCC(F)(F)F)=N1 LTUNNEGNEKBSEH-UHFFFAOYSA-N 0.000 description 11
- 150000002596 lactones Chemical class 0.000 description 11
- 150000004714 phosphonium salts Chemical class 0.000 description 11
- VBQCHPIMZGQLAZ-UHFFFAOYSA-N phosphorane Chemical class [PH5] VBQCHPIMZGQLAZ-UHFFFAOYSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 210000000744 eyelid Anatomy 0.000 description 10
- 229930195733 hydrocarbon Natural products 0.000 description 10
- 239000012442 inert solvent Substances 0.000 description 10
- 239000004215 Carbon black (E152) Substances 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000012025 fluorinating agent Substances 0.000 description 9
- 210000000554 iris Anatomy 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010020565 Hyperaemia Diseases 0.000 description 8
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 239000002798 polar solvent Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- BXQJOBXGDHVCEY-UHFFFAOYSA-N 1-(3,4-dichlorophenoxy)ethanol Chemical compound CC(O)OC1=CC=C(Cl)C(Cl)=C1 BXQJOBXGDHVCEY-UHFFFAOYSA-N 0.000 description 7
- 206010015946 Eye irritation Diseases 0.000 description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 7
- 239000003889 eye drop Substances 0.000 description 7
- 229940012356 eye drops Drugs 0.000 description 7
- 231100000013 eye irritation Toxicity 0.000 description 7
- 229910052744 lithium Inorganic materials 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 5
- VVQGJRMTFDPECJ-UHFFFAOYSA-N 1-(3-fluorophenoxy)ethanol Chemical compound FC=1C=C(OC(C)O)C=CC=1 VVQGJRMTFDPECJ-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 210000002159 anterior chamber Anatomy 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000004210 ether based solvent Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002997 ophthalmic solution Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MWIZRZPCJMZUNG-UHFFFAOYSA-N 1-(3,5-dichlorophenoxy)ethanol Chemical compound CC(O)OC1=CC(Cl)=CC(Cl)=C1 MWIZRZPCJMZUNG-UHFFFAOYSA-N 0.000 description 4
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical class [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 4
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- FNNSOTNVIWRTTO-UHFFFAOYSA-N CC(O)OC1=CC(=CC(=C1)F)F Chemical compound CC(O)OC1=CC(=CC(=C1)F)F FNNSOTNVIWRTTO-UHFFFAOYSA-N 0.000 description 3
- 208000028006 Corneal injury Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- FPABVZYYTCHNMK-YNRDDPJXSA-N PGF2alpha isopropyl ester Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C FPABVZYYTCHNMK-YNRDDPJXSA-N 0.000 description 3
- PJDMFGSFLLCCAO-NVRZHKMMSA-N PGF2alpha methyl ester Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC PJDMFGSFLLCCAO-NVRZHKMMSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 210000000826 nictitating membrane Anatomy 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 3
- CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 150000007970 thio esters Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 2
- 125000006052 1-methyl-3-pentenyl group Chemical group 0.000 description 2
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000004292 cyclic ethers Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004957 naphthylene group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- UFXIRMVZNARBDL-UHFFFAOYSA-N trifluoro(morpholin-4-yl)-$l^{4}-sulfane Chemical compound FS(F)(F)N1CCOCC1 UFXIRMVZNARBDL-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- POJYLUCHZKGWIQ-UHFFFAOYSA-N 1-fluoro-1-phenoxyethanol Chemical compound CC(O)(OC1=CC=CC=C1)F POJYLUCHZKGWIQ-UHFFFAOYSA-N 0.000 description 1
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- AAYWIXGLVAEPTP-UHFFFAOYSA-N 2,3-dimethylbutan-2-ylboron Chemical compound [B]C(C)(C)C(C)C AAYWIXGLVAEPTP-UHFFFAOYSA-N 0.000 description 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- COAUHYBSXMIJDK-UHFFFAOYSA-N 3,3-dichloro-1,1,1,2,2-pentafluoropropane Chemical compound FC(F)(F)C(F)(F)C(Cl)Cl COAUHYBSXMIJDK-UHFFFAOYSA-N 0.000 description 1
- RVGLUKRYMXEQAH-UHFFFAOYSA-N 3,3-dimethyloxetane Chemical compound CC1(C)COC1 RVGLUKRYMXEQAH-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical compound C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 238000006596 Alder-ene reaction Methods 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- HEDFOPRFWRIRLE-UHFFFAOYSA-N CN1C(CCCC1(C)C)C.[Li] Chemical compound CN1C(CCCC1(C)C)C.[Li] HEDFOPRFWRIRLE-UHFFFAOYSA-N 0.000 description 1
- 101100313164 Caenorhabditis elegans sea-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015237 Erythema of eyelid Diseases 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000609789 Kobus vardonii Species 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000004808 allyl alcohols Chemical group 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QLULGSLAHXLKSR-UHFFFAOYSA-N azane;phosphane Chemical class N.P QLULGSLAHXLKSR-UHFFFAOYSA-N 0.000 description 1
- 239000010953 base metal Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004409 cloprostenol Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000478 corneal permeability Toxicity 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- OIKHZBFJHONJJB-UHFFFAOYSA-N dimethyl(phenyl)silicon Chemical compound C[Si](C)C1=CC=CC=C1 OIKHZBFJHONJJB-UHFFFAOYSA-N 0.000 description 1
- AJQDMTKWSVMVQA-UHFFFAOYSA-N dimethylamino thiohypofluorite Chemical compound CN(SF)C AJQDMTKWSVMVQA-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- WOXXLSARQWGEHP-UHFFFAOYSA-L disodium dihydrogen phosphate phosphoric acid hydroxide Chemical compound [OH-].[Na+].[Na+].OP(O)(O)=O.OP(O)([O-])=O WOXXLSARQWGEHP-UHFFFAOYSA-L 0.000 description 1
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 description 1
- 229950009951 fluprostenol Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical compound C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- BJHIKXHVCXFQLS-OTWZMJIISA-N keto-L-sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- GQNMAZUQZDEAFI-UHFFFAOYSA-N lithium;1h-naphthalen-1-ide Chemical compound [Li+].[C-]1=CC=CC2=CC=CC=C21 GQNMAZUQZDEAFI-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- UPRXAOPZPSAYHF-UHFFFAOYSA-N lithium;cyclohexyl(propan-2-yl)azanide Chemical compound CC(C)N([Li])C1CCCCC1 UPRXAOPZPSAYHF-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001512 metal fluoride Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- CRKIOGSAUZSJOT-UHFFFAOYSA-N phenoxy(propyl)phosphinic acid Chemical compound CCCP(O)(=O)OC1=CC=CC=C1 CRKIOGSAUZSJOT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- GWLJTAJEHRYMCA-UHFFFAOYSA-N phospholane Chemical compound C1CCPC1 GWLJTAJEHRYMCA-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- GXBBCEZQOPFZFX-UHFFFAOYSA-N potassium;3-aminopropylazanide Chemical compound [K+].NCCC[NH-] GXBBCEZQOPFZFX-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- ABTOQLMXBSRXSM-UHFFFAOYSA-N silicon tetrafluoride Chemical compound F[Si](F)(F)F ABTOQLMXBSRXSM-UHFFFAOYSA-N 0.000 description 1
- 229940096017 silver fluoride Drugs 0.000 description 1
- REYHXKZHIMGNSE-UHFFFAOYSA-M silver monofluoride Chemical compound [F-].[Ag+] REYHXKZHIMGNSE-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- QHMQWEPBXSHHLH-UHFFFAOYSA-N sulfur tetrafluoride Chemical compound FS(F)(F)F QHMQWEPBXSHHLH-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- XIRDWFIDMQZDEU-UHFFFAOYSA-N tetrafluoro(phenyl)-$l^{5}-phosphane Chemical compound FP(F)(F)(F)C1=CC=CC=C1 XIRDWFIDMQZDEU-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 1
- 239000005052 trichlorosilane Substances 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004360 trifluorophenyl group Chemical group 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- NFHRNKANAAGQOH-UHFFFAOYSA-N triphenylstannane Chemical compound C1=CC=CC=C1[SnH](C=1C=CC=CC=1)C1=CC=CC=C1 NFHRNKANAAGQOH-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002567 weak irritant Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
Definitions
- the present invention relates to a fluorine-containing prostaglandin derivative having a fluorine atom at the 15-position and a salt thereof, and a drug containing the same as an active ingredient, particularly a drug for preventing or treating eye diseases.
- Natural prostaglandin is a group of physiologically active substances synthesized in vivo, and regulates the cellular functions of various tissues in the body as local hormones having various physiological activities.
- PGFs which are a type of natural PG, are used as labor inducers and animal sexual synchronizing agents because they have uterine contraction, anti-pregnancy and estrous cycle control. Therefore, the development of PGF derivatives that are more effective as these drugs and have no side effects is being studied at home and abroad.
- prostaglandins generally have various biological activities, it is necessary to skillfully utilize the difference in selectivity to receptors due to subtle structural changes in order to obtain derivatives that selectively exhibit the desired action.
- the present inventors focused on the ⁇ chain of PG and predicted that the position, type and number of substituents of the terminal aryl group or heteroaromatic ring would greatly affect the selectivity. It was also predicted that the lipophilicity of the compound would greatly contribute to the absorption and pharmacological effects in vivo, and that the rate of hydrolysis of the ester in vivo for carboxylic acid derivatives would contribute to the sustainability.
- PGFs which are a type of natural PG
- PGFs are known to reduce intraocular pressure when administered locally to the eye, and have been expected to be applied as therapeutics for ocular hypertension and glaucoma ( US P 4, 599, 3 53 etc.).
- PGF derivatives free of these side effects is being actively conducted inside and outside Japan.
- PGF derivatives having a ring structure in the ⁇ chain are also known. Schernschand et al.
- 1 5- Furuoro 1 5 Dokishi PGF 2 prostaglandin F derivatives having a fluorine atom in 1 position 5 in addition to ⁇ is not known at all
- 1 5 Furuoro 1 having a particularly non-naturally occurring side chains of the 5 Dokishi PGF 2 is not known a synthesis method for derivatives.
- synthesis of 1 5 Furuoro 1 5 Dokishi PGF 2 Q in the above documents, after fluorination of 1 5 of the native PGA 2, 1 5 Furuoro - 1 5 Dokishi converted into PGE 2, carried out by highly impractical way that by reducing the 9-position of Karuboeru groups leads to 1 5 full Oro 1 5 Dokishi P GF 2 u are (Dokl. Akad.
- prostaglandins generally have various biological activities
- the present inventors have focused on the ⁇ chain of prostaglandin, and have predicted that the position, type and number of substituents of the terminal aryl group or heteroaromatic ring will greatly affect the selectivity.
- the invention predicted that the lipophilicity of the compound greatly contributes to the intraocular transferability and intraocular pressure lowering effect in the case of eye drops, and that in the case of carboxylic acid derivatives, the rate of ester hydrolysis in the living body is involved in the sustainability. Disclosure of
- the present inventors have developed 15-fluoro-15-deoxy PGF 2 . And its derivatives were measured for physiological activity and their usefulness as pharmaceuticals was examined. Furthermore, as a derivative of 15-fluoro 15-dexoxy PGF 2 ⁇ ⁇ , a compound having an aryloxy group in its ⁇ chain and derivatized with a carboxylic acid or hydroxyl group of prostaglandin was also measured for physiological activity. was examined the utility of its pharmaceutically result, the present inventors have 1 5 -.
- Furuoro 1 5 Dokishi PGF 2 alpha and derivatives thereof have similar intraocular pressure-lowering effect and natural prostaglandins F such
- the present inventors have found that eye irritation and effects on the eye tissue such as the cornea, iris, conjunctiva, etc. are further improved and the durability is good.
- the present invention provides a novel 15-fluoro-15-dexoxy PGF 2 Q derivatives, a medicament for the derivative as an active ingredient, and, the 1 5 full Ruoro 1 5 - is the following invention relating to Dokishi PGF 2 sigma or pharmaceutical use for eye diseases derivatives thereof.
- a fluorine-containing prostaglandin derivative represented by the following general formula (1) (however, excluding 15-fluoro-15-dexoxy PGF 2a ) or a salt thereof, and a medicament containing them as an active ingredient.
- a medicament for preventing or treating eye diseases comprising a fluorine-containing prostaglandin derivative represented by the following general formula (1) or a salt thereof as an active ingredient.
- R 1 substituted or unsubstituted alkyl group having 3 to 8 carbon atoms, substituted or unsubstituted alkenyl group having 3 to 8 carbon atoms, substituted or unsubstituted alkynyl group having 3 to 8 carbon atoms, substituted or unsubstituted A substituted or unsubstituted cycloalkyl group having 3 to 8 carbon atoms, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryloxyalkyl group;
- R 2 and R 3 each independently represent a hydrogen atom, an acyl group, or the following single bond: X: — CH 2 —, — O—, or — S—,
- R 4 , R 5 , R 6 , R 7 each independently represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, or an aralkyl group;
- R ′ and R 2 are an acyl group, or Z is —OR 4 (However, R '1 is not a hydrogen atom), single N HCOR 5, -NH S 0 2 R 6 , or - a compound is SR 7 is preferred.
- lower for an organic group means 1 to 6 carbon atoms. More preferred lower organic groups are organic groups having 1 to 4 carbon atoms.
- the “alkyl group” may be linear or branched, and a lower alkyl group is preferable unless otherwise specified. Suitable examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a t-butyl group, a pentyl group and a hexyl group.
- alkenyl group a lower alkenyl group is preferred unless otherwise specified, and more preferably a C 2-6 unsaturated alkenyl group.
- alkynyl group is preferably a lower alkynyl group unless otherwise specified, and more preferably a straight-chain or branched alkynyl group having 2 to 6 carbon atoms and one unsaturated group. Examples include 1-propynyl, 2-propynyl, 3-butynyl, 3-pentynyl, 4-hexynyl and the like.
- alkoxy group a wide range of general alkoxy groups is used, but a lower alkoxy group is preferable, and a linear or branched alkoxy group having 1 to 4 carbon atoms is more preferable. , Methoxy, ethoxy, propoxy and butoxy groups.
- Halogen atom means a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- Aryl group refers to a monovalent aromatic hydrocarbon group, which may have a substituent (eg, a lower alkyl group, a halogen atom, a lower alkoxy group, a lower alkylamino group, etc.), and is preferably phenyl.
- a halophenyl group for example, a chlorophenyl group, a fluorophenyl group, a bromophenyl group, etc.
- a dihalophenyl group for example, a dichlorophenyl group, a difluorophenyl group, a dibromo group.
- a phenyl group a triphenyl phenyl group (eg, a trichlorophenyl group, a trifluorophenyl group, a tribromophenyl group, etc.), an alkoxyphenyl group (eg, a methoxyphenyl group, an ethoxyphenyl group, etc.).
- the "aralkyl group” refers to an aryl group-substituted alkyl group, and examples of the aryl group as the substituent include those described above.
- the alkyl group preferably has 1 to 4 carbon atoms. Suitable examples thereof include a benzyl group, a benzhydryl group, a trityl group, a phenethyl group and the like.
- Cycloalkyl group represents an unsubstituted or substituted 3- to 8-membered cycloalkyl group.
- substituent include a lower alkyl group, a halogen atom and an alkoxy group.
- Halogenated alkyl group means a lower halogenated alkyl group halogenated with one or more halogen atoms. Examples thereof include a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a trifluoroethyl group, a pentafluoroethyl group, a chloromethyl group, a dichloromethyl group, a trichloromethyl group, and a bromomethyl group.
- acyl group refers to a monovalent or polyvalent group which can be obtained by removing a hydroxyl group from all carboxyl groups of a carboxylic acid.
- the carboxylic acids include saturated or unsaturated aliphatic carboxylic acids, carbocyclic carboxylic acids, and heterocyclic carboxylic acids.
- Carbocyclic rubonic acid refers to saturated or unsaturated cyclic aliphatic carboxylic acids and aromatic rubonic acids.
- fluorinated prostaglandin derivative (1) represented by the above general formula (1)
- the following compounds are preferred from the viewpoint of physiological activity and physical properties.
- A is preferably a vinylene group or an ethylene group, and particularly preferably a vinylene group.
- the vinylene group includes cis and trans vinylene groups, and among them, a transyl vinylene group is particularly preferred.
- X is preferably —CH 2 —.
- the overlap between the solid line and the broken line is a cis double bond.
- 'As is natural PGF 2 u organic groups corresponding to the omega chain portion (R' R omega chain portion of the case parts of the non-are non-naturally occurring PGF 2 alpha) and various non-natural PGF 2 a class
- An organic group corresponding to is preferred.
- Such organic groups include alkyl groups having 3 to 8 carbon atoms, alkenyl groups having 3 to 8 carbon atoms, alkynyl groups having 3 to 8 carbon atoms, cycloalkyl groups having 3 to 8 carbon atoms in the ring, aralkyl groups, There are aryloxy groups having aryl such as phenyl group, and these groups having various substituents.
- the alkyl group may have an organic group having a ring such as a cycloalkyl group as a substituent
- the alkenyl group or the alkynyl group may have an organic group having a ring such as an aryl group or a cycloalkyl group as a substituent. It may have a group.
- It may be an alkyl group substituted with an alkyl group, an alkenyl group substituted with a cycloalkyl group, an alkenyl group substituted with an aryl group, or the like.
- carbon atoms of a chain organic group such as an alkyl group may be substituted with an oxygen atom or a sulfur atom, and an organic group having a ring such as a cycloalkylene group or a arylene group is inserted between carbon atoms of the chain organic group. It may be done.
- the ring may have a chain organic group such as an alkyl group as a substituent.
- the substituent for R 1 include the above substituents, a halogen atom, an oxygen atom-containing substituent, a sulfur atom-containing substituent, a nitrogen atom-containing substituent, and the like.
- a linear alkyl group, alkenyl group and alkynyl group having 5 to 6 carbon atoms, and monomethyl-substituted and dimethyl-substituted forms thereof are particularly preferred.
- Specific examples of the linear R 1 include the following groups. Among them, n-pentyl, 2-methylhexyl, 1-methyl-3-pentynyl, 1-methyl-3-hexynyl, and 1,1-dimethyl-3-hexynyl are particularly preferred.
- a substituted or unsubstituted cycloalkyl group R 1 a cycloalkyl group having 3 to 8 carbon atoms and a cycloalkyl group substituted with one or more lower alkyl groups are preferable.
- an unsubstituted cyclopentyl group, an unsubstituted cyclohexyl group, a cyclopentyl group substituted with an alkyl group having 1 to 4 carbon atoms, 1 carbon atom Cyclohexyl groups substituted with alkyl groups of 4 to 4 are preferred.
- R 1 which is a substituted or unsubstituted aralkyl group, an alkyl group containing a benzene ring, a furan ring, a thiophene ring, a naphthylene ring, etc., substituted with a halogen atom, a halogenated alkyl group, an alkoxy group, a hydroxyl group, etc. Alkyl groups are preferred.
- the alkyl portion of the aralkyl group (that is, the alkylene group) preferably has 1 to 4 carbon atoms.
- a particularly preferred aralkyl group is an alkyl group having 1 to 2 carbon atoms having a phenyl group, or an 1 to 2 carbon atom having a phenyl group substituted with 1 to 2 lower alkyl groups or halogen atoms. It is an alkyl group.
- the aryl group may be replaced by a halogen atom, a halogenated alkyl group, an alkoxy group, a hydroxyl group, etc., a benzene ring, a furan ring, An aryloxyalkyl group containing a thiophene ring, a naphthylene ring or the like is preferred.
- the aryl group is preferably a phenyl group, and the phenyl group preferably has 1 to 3 halogen atoms or halogenated alkyl groups.
- the alkyl group substituted with an aryloxy group preferably has from 1 to 3 carbon atoms.
- Particularly preferred specific aryloxy groups are phenoxymethyl, 3-chlorophenoxymethyl, 3-fluorophenoxymethyl, 3-trifluoromethylphenoxymethyl, 3,5- Dichlorophenoxymethyl group, 3,4-dichlorophenoxymethyl group, 3,5-difluorophenoxymethyl group, 3,4-difluorophenoxymethyl group, 3,5-bis (trifluoromethyl ) Phenoxymethyl group and 3,4-bis (trifluoromethyl) phenoxymethyl group.
- an alkyl group having 1 to 4 carbon atoms which is substituted with the above-mentioned cycloalkyl group, which is one kind of an alkyl group having a substituent, is preferable.
- the cycloalkyl group is preferably a cyclopentyl group and a cyclohexyl group.
- an alkyl group having 1 to 2 carbon atoms is preferable. Specific examples of this group include a cyclopentylmethyl group, a 2-cyclopentylethyl group, and a cyclohexylmethyl group.
- R ' is the substituted or unsubstituted aryloxyalkyl groups and substituted or unsubstituted aralkyl groups as described above.
- substituted phenoxymethyl groups such as 3,5-dichlorophenoxymethyl group, 3,4-dichlorophenoxymethyl group, and 3-chlorophenoxymethyl group, phenylmethyl group, and 3-methylphenylmethyl group
- substituted phenylmethyl groups such as trifluoromethylphenylmethyl group, 3,5-dichlorophenylmethyl group, and 3,4-dichlorophenylmethyl group are preferred.
- a halogen atom-substituted phenoxymethyl group such as a 3,5-dichlorophenoxymethyl group, a 3,4-dichlorophenoxymethyl group, a 3-chlorophenoxymethyl group, and a phenoxymethyl group are preferable.
- R 2 and R 3 are each independently a hydrogen atom or an acyl group, or a single bond described later.
- both R 2 and R ′ are hydrogen atoms, or one is an acyl group and the other is a hydrogen atom.
- R 2 is preferably an acyl group.
- Compounds in which at least one of R 2 and R 3 is an acyl group are useful as prodrugs because they can be converted to biologically active compounds by hydrolysis in vivo.
- the acyl group an acyl group having 2 to 20 carbon atoms, particularly an aliphatic hydrocarbon group having 2 to 20 carbon atoms is preferable.
- a fluorine-containing prostaglandin derivative in which either R 2 or R 3 is an aliphatic linear hydrocarbon-based acyl group having 4 or more carbon atoms is useful as a prodrug having improved fat solubility.
- Z is one OR 4, -NHCOR 5, - NH S 0 2 R e, - SR 7 , or the R 2 or R 3 and Z represents a single bond jointly.
- R 2 or R 3 and Z together represent a single bond a compound in which Z is ⁇ H and at least one of R 2 or R 3 is a hydrogen atom (a hydroxyl group at the ⁇ -chain terminal)
- the compound having a hydroxyl group in at least one of the 9-position and the 11-position), the ⁇ -chain terminal and the 9-position or 11-position are formed by an esterification reaction between the carboxyl group and the hydroxyl group. Represents cyclization by a stele bond.
- the compound cyclized by the ester bond is useful as a prodrug because it can be converted into a biologically active compound by hydrolysis in a living body.
- alkyl group, alkenyl group, alkynyl group, cycloalkyl group, Ariru Alkyl group, alkenyl group, alkynyl group, and the alkyl group portion of the aralkyl group may be linear or branched, and include various groups such as a halogen atom. Further, the ring of the cycloalkyl group, aryl group and aralkyl group may have an alkyl group or other substituents. for example, a substituent as described in the description of the R 1.
- the alkyl group as R "to R 7, an alkenyl group, the alkynyl group, their respective number of carbon atoms is 20 or less, particularly 8 or less are preferable.
- Specific these chain hydrocarbon group a methyl group , Ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-decyl, 1-methylpentyl, 1, Examples include a 1-dimethylpentyl group, a 1-methylhexyl group, a 2-methylpentyl group, a 2-methylhexyl group, etc.
- the alkenyl group includes an aryl group, a 2-butenyl group, a 3-pentenyl group, Examples include 1-methyl-3-pentenyl group, 1-methyl-3-hexenyl group, 1,1-dimethyl-3-pentenyl group, 1,1-dimethyl-3-hexenyl group, and the like.
- Gill group 3-pentynyl group, 1-methyl-3-pentynyl group, 1_methyl-3-hexynyl group, 1,1-dimethyl-3-pentynyl group, 1,1-dimethyl-3-hexynyl group, etc. Is mentioned.
- Examples of the substituted alkyl group represented by R 4 to R 7 include a halogen atom-substituted alkyl group and a cycloalkyl group-substituted alkyl group.
- the halogen atom-substituted alkyl group preferably has 6 or less carbon atoms.
- the alkyl group portion of the substituted alkyl group preferably has 1 to 2 carbon atoms.
- Examples of the halogen-substituted alkyl group include a trifluoromethyl group and a pentafluoroethyl group. You.
- Examples of the cycloalkyl group-substituted alkyl group include a cyclobutylmethyl group, a cyclopentylmethyl group, a cyclohexylmethyl group, and the like.
- These carbon atoms as cycloalkyl group as to R 7 is 1 0 or less.
- Specific examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a 2,2-dimethylcyclopropyl group, a 3-cyclopentenyl group, a 3-cyclohexynyl group, and a cyclohexyl group.
- the aryl group as R to R 7 is preferably a substituted or unsubstituted phenyl group.
- an alkyl group preferably having 4 or less carbon atoms
- a halogenated methyl group preferably having 4 or less carbon atoms
- a halogen atom preferably having 4 or less carbon atoms
- an alkoxy group preferably having 4 or less carbon atoms
- an acyl group preferably having 4 or less carbon atoms
- the aralkyl group represented by R 4 to R 7 is preferably an aralkyl group comprising a phenyl group and an alkyl group having 4 or less (preferably 1 to 2) carbon atoms.
- the phenyl group in these groups may have a substituent such as an alkyl group (preferably having 4 or less carbon atoms), a halogenated methyl group, a halogen atom, an alkoxy group, an acyl group, an acylamino group, and a nitro group.
- the alkyl group portion of the aralkyl group may have a branch.
- Each of R 4 to R 7 is preferably an alkyl group, a cycloalkyl group, or an aralkyl group which may have a substituent.
- a substituent a halogen atom or an alkyl group having 4 or less carbon atoms bonded to a ring is preferable.
- R 4 to R 7 are each an alkyl group, and in addition, R fi is an alkyl group substituted with a halogen atom.
- Z is particularly preferably a group represented by -OR ".
- R is a hydrogen atom or a carbon atom having 1 to 20 carbon atoms such as an alkyl group, a cycloalkyl group, and an aralkyl group. It is preferably a hydrogen group.
- Compounds in which R 4 is a hydrocarbon group or the like are useful as prodrugs because they can be converted into biologically active compounds by hydrolysis in vivo.
- the type of the hydrocarbon group can be selected to improve the fat solubility of the compound.
- Most preferred Z is a hydroxyl group, an isopropoxy group, an ethoxy group, a methoxy group, an isobutoxy group, a cyclohexyloxy group, and a benzyloxy group.
- the fluorinated prostaglandin derivative in the present invention has an acidic group such as a carboxy group
- the fluorinated prostaglandin derivative may be a salt with a base.
- the salt with a base include alkaline metal salts such as sodium salt and alkaline earth metal salts, alkaline earth metal salts such as calcium salt and magnesium salt, and ammonium salts such as unsubstituted ammonium salts and alkyl-substituted ammonium salts. And salt.
- the salt with an acid examples include inorganic acid salts such as hydrochloride, sulfate, and phosphate, and organic acid salts such as acetate, oxalate, citrate, succinate, and p-toluenesulfonate. There is.
- Fluorinated prostaglandin derivative in the present invention by a general prostaglandin F 2 alpha synthesis After synthesis of prostaglandin skeleton, 1 5-position It can be synthesized by converting a hydroxyl group into a fluorine atom by a fluorination reaction.
- Known methods can be applied as a method for synthesizing brostaglandin F2a. For example, using a C orey lactone as a starting material, an ⁇ chain is first introduced, and converted to a C orey lactone with an ⁇ chain.
- a prostaglandin F 2 u skeleton can be synthesized to produce prostaglandins, which are raw materials for fluorination.
- the hydroxyl group at the 15-position of this raw material prostaglandin is fluorinated.
- fluorination is obtained as a main product of a fluorinated product having a stereochemistry reversed from that of a hydroxyl group. Therefore, in order to efficiently obtain a fluorinated product having the same orientation as a natural type hydroxyl group, a non-natural type hydroxyl group is used. It may be synthesized.
- Various known fluorination methods can be applied to fluorinate the hydroxyl group and convert it to the fluorinated prostaglandin derivative represented by the general formula (1). For example, a method of reacting in an inert solvent using various nucleophilic fluorinating agents is employed.
- the raw material prostaglandins have a functional group that may be fluorinated during the fluorination reaction, it is preferable that the functional group is protected by a protecting group in advance.
- a protecting group for example, when R 2 or R 3 is a hydrogen atom, it is preferable to protect with a protecting group, fluorinate the hydroxyl group at the 15-position, and then deprotect to obtain the fluorine-containing prostaglandin derivative of the present invention.
- Examples of the protecting group include a triorganosilyl group, an acyl group, an alkyl group, an aralkyl group, and a cyclic ether group.
- a cyclic acetal, a cyclic ester, a cyclic orthoester, a cyclic silyl ether, a cyclic carbonate, a cyclic boronate, etc. which are general protecting groups for 1,3-diol, can also be used.
- the acyl group for protecting the hydroxyl group at the 9-position or 11-position may be the same as or different from R 2 or R 3 in the case of an acyl group.
- Compounds having an acyl group other than those used as protecting groups can be synthesized by removing the protecting group and then introducing a new acyl group.
- Triorganosilyl groups include alkyl, aryl, aralkyl, It is a group in which three organic groups such as a coxyl group are bonded to a silicon atom, and a triorganosilyl group having at least three groups of at least one selected from a lower alkyl group and an aryl group is particularly preferable.
- a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, a triethylsilyl group, a triphenylsilyl group, a triisopropylsilyl group and the like are preferable.
- the acetyl group is preferably an acetyl group, a trifluoroacetyl group, a bivaloyl group, a benzoyl group or a P-phenylpentyl group
- the cyclic ether group is preferably a tetrahydroviranyl group ⁇ tetrahydrofuranyl group.
- the alkyl group and aralkyl group which may have a substituent include an alkoxyalkyl group such as a methoxymethyl group, a 1-ethoxyxyl group, a 2-methoxyxoxymethyl group, a benzyl group, and a benzyl group.
- Methyl acetal, ethylidene acetal, isopropylidene acetal, etc. are preferred as the cyclic acetal and cyclic ketone having a toxicoxyl group, a trityl group, etc., and methoxymethylene acetal, dimethoxymethylene as the cyclic orthoester Acetal and the like are preferred.
- the cyclic silyl ether a 1,3- (1,1,3,3-tetraisopropyldisiloxanilidene) derivative and the like are preferable, and as the cyclic boronate, phenylpolonate and the like are preferable.
- the protecting group for a hydroxyl group as described above can be converted into a hydroxyl group by a conventional method.
- a conventional method For example, "New Experimental Chemistry Course 14 Synthesis and Reaction of Organic Compounds (I), (II, (V)” (Maruzen), “Protective Grooves in Organic Synthesis” (T.W.Greene, J.Wiley & S. ons) can be easily converted to a hydroxyl group.
- a fluorinating agent is used in a method for producing a fluorine-containing prostaglandin derivative by fluorinating a raw material prostaglandin having a hydroxyl group at the 15-position.
- the fluorination is preferably carried out in an inert solvent. Further, the fluorination may be performed in the presence of a base.
- the reaction temperature of the fluorination is usually about -150 to 110, preferably 180 to 14 °.
- Fluorinated prostaglandins obtained by fluorinating raw broths The fluorinating agent used in the method for producing a derivative is not particularly limited, and a known or well-known nucleophilic fluorinating agent can be used.
- nucleophilic fluorinating agents described in documents such as Tomoya Kitazume, Takashi Ishihara, and Takeo Taguchi “Fluorine Chemistry” (Kodansha Scientific) can be used.
- fluoroalkyls such as dialkylaminosulfur trifluoride derivatives, tetrafluorophenylphosphorane, adducts of ethylamine-cloth trifluorothene, and adducts of pentylamine-hexafluorolop pen.
- Amine reactants hydrogen fluoride amine complexes such as HF-pyridine and HF-triethylamine, metal fluorides such as silicon tetrafluoride, sulfur tetrafluoride, potassium fluoride, cesium fluoride and silver fluoride, Examples thereof include ammonium phosphonium salts such as rabutylammonium fluoride and tetraethylammonium fluoride tetrabutylfluorophosphorane.
- nucleophilic fluorinating agents in terms of yield and selectivity are dialkylaminosulfur trifluoride derivatives, specifically, morpholinosulfur trifluoride, piberidinosulfur trifluoride, and getylaminosulfur trifluoride. And dimethylaminosulfur fluoride.
- the hydroxyl group of the raw prostaglandins may be directly fluorinated with these fluorinating agents. Further, in order to increase the reactivity of fluorination or suppress a side reaction, the hydroxyl group may be converted to a derivative such as sulfonatodisilyl ether before fluorination.
- these sulfonates methanesulfonate, p-toluenesulfonate, benzenesulfonate, trifluoromethanesulfonate and the like are preferable, and as the silyl ether, trimethylsilyl ether and the like are preferable.
- the amount of the fluorinating agent is suitably about 0.5 to 20 parts by weight, preferably about 1 to 5 parts by weight, based on 1 part by weight of the raw material prosgin glandins used as a substrate. Good.
- a halogen-based solvent As the inert solvent, a halogen-based solvent, an ether-based solvent, a hydrocarbon-based solvent, an polar solvent, or a mixed solvent thereof is preferable.
- the amount of the inert solvent is usually about 5 to 100 parts by weight, preferably 10 to 100 parts by weight, per 1 part by weight of the prostaglandins.
- Preferred examples of the halogen-based solvent include methylene chloride, chloroform, 1,2-dichloromethane, carbon tetrachloride, chlorobenzene, and dichloropentafluoropropane.
- Ether solvents include getyl ether, tetrahydrofuran
- THF 1,4-dioxane, dimethyloxetane, diglyme, t-butyl methyl ether and the like are preferred.
- hydrocarbon solvent hexane, toluene, benzene, pentane, xylene, petroleum ether, and the like are preferable.
- polar solvents include dimethyl sulfoxide, hexamethylphosphoramide [HMPA], 1,3-dimethyl-3,4,5,6-tetrahydro-l-2 (1H) -pyrimidinone [DMPU], 1,3-Dimethyl-2-imidazolidinone [DM I], N, N, N ', ⁇ '-tetramethylethylenediamine [TMEDA], etc. are preferred.
- amines such as tertiary amines and aromatic amines, and salts of alkali metal and alkaline earth metal are preferable.
- Specific examples include triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, dimethylaminopyridine, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and hydrogencarbonate.
- fluorine-containing prostaglandin derivative (1) of the present invention has the following general formula:
- a phosphorane (3) represented by the following general formula (3) can also be produced by allowing a phosphorane (3) represented by the following general formula (3) to act on the fluorinated lactol represented by (2).
- a fluorinated alcohol represented by the following general formula (4) is obtained by fluorinating an alcohol represented by the following general formula (5) (hereinafter, referred to as an alcohol (5)). Lactones (hereinafter referred to as fluorinated lactones (4)), and then reducing the fluorinated lactones (4) to produce the fluorinated lactones represented by the general formula (2) (
- fluorinated lactols (2) will be produced.
- a phospholane represented by the general formula (3) (hereinafter, referred to as a phosphorane (3)) is produced from a phosphonium salt represented by the following general formula (6) (hereinafter, referred to as a phosphonium salt (6)).
- a phosphonium salt represented by the following general formula (6) (hereinafter, referred to as a phosphonium salt (6)).
- R IQ in (6) represents a substituted or unsubstituted aryl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aralkyl group, or a dialkylamino group
- Y represents a chlorine atom, a bromine atom, or an iodine atom. Represents a halogen atom.
- Alcohols (5) are basically known compounds and can be produced by known methods.
- the above-mentioned fluorination method can be basically used. The same applies to the fluorinated hydroxyl group and configuration, the protection of the non-fluorinated hydroxyl group, the fluorinating agent and solvent used, and the fluorination conditions such as the reaction temperature and the use of a base.
- the fluorinated lactones (4) obtained by the above fluorination reaction are then reduced to produce fluorinated lactols (2).
- a method of reacting a reducing agent in an inert solvent is usually used.
- the amount of the reducing agent used in this reduction reaction is usually 0.01 to 50 with respect to 1 equivalent of the fluorinated lactone (4). Equivalents are appropriate, with 5 to 20 equivalents being preferred.
- the reaction temperature is preferably about ⁇ 150 to about 100 ° C., particularly preferably about 180 to 0 ° C.
- Examples of the reducing agent include diisobutylaluminum hydride [DI BAH], dialkylaluminum alkoxide, lithium aluminum hydride, tributyltin hydride, triphenyltin hydride, triethylsilane, trichlorosilane, dimethylphenylsilane, diphenylsilane, and borohydride.
- DI BAH diisobutylaluminum hydride
- dialkylaluminum alkoxide lithium aluminum hydride
- tributyltin hydride triphenyltin hydride
- triethylsilane triethylsilane
- trichlorosilane dimethylphenylsilane
- diphenylsilane diphenylsilane
- borohydride borohydride
- Inert solvents used in the reduction reaction include ether solvents and hydrocarbon solvents.
- a polar solvent, or a mixed solvent thereof is preferred.
- Specific examples of the ether solvent, the hydrocarbon solvent, and the polar solvent are preferably the ether solvent, the hydrocarbon solvent, and the polar solvent described as specific examples in the description of the fluorination reaction. Of these, getyl ether, THF, t-butyl methyl ether, toluene, and benzene are particularly preferred.
- the configuration of the hydroxyl group of the fluorinated lactols (2) generated by the reduction reaction is not particularly limited.
- the phosphoranes (3) are produced from the corresponding phosphonium salts (6) in an inert solvent in the presence of a base.
- the generated phosphoranes (3) are usually used in the Wi Uig reaction with fluorinated lactols (2) without isolation.
- Methods for producing phosphoholanes (3) from the corresponding phosphonium salts (6) are described in, for example, “New Experimental Chemistry Course 14 Synthesis and Reaction of Organic Compounds (I)” (Maruzen), “Fourth Edition Chemistry Course 19 Organic Synthesis I, Hydrocarbons and Halogen Compounds ”(Maruzen), and the method described in Schaaf et al. (J. Med. Chem. 22.1340 (1979)).
- Z in the phosphoranes (3) and the phosphonium salts (6) may be any of the above, but is usually a hydroxyl group in these compounds (ie, OR 4 in which R 4 is a hydrogen atom).
- a fluorinated prostaglandin derivative (1) in which Z is a hydroxyl group is obtained.
- a fluorine-containing prosiglandin derivative (1) in which Z is a group other than a hydroxyl group and Z is a group other than a hydroxyl group can also be produced.
- Z is - NHCOR 5 or when converting the Hosuhoniumu salts (6) is an NHS_ ⁇ 2 R fi to phosphoranes (3), phosphoranes (3) in an NHC OR 5 or _NHS_ ⁇ 2 nitrogen R 6 Hydrogen atoms bonded to atoms may be converted to metal ions. Eventually, the reaction product obtained by reacting this with the fluorinated lactols (2) by W tig reaction also turns this part into gold ions. This metal ion is used when converting phosphonium salts (6) to phosphoranes (3). Derived from the base metal ions (especially alkali metal ions and alkaline earth metal ions). This metal ion can be converted to a hydrogen atom by a treatment such as hydrolysis if necessary.
- the amount of the phosphorane (3) to be used is usually about 0.1 to 20 equivalents, preferably 1 to 10 equivalents, per 1 equivalent of the fluorinated lactol (2). .
- the reaction of phosphoranes (3) on fluorinated lactols (2) is a reaction generally called a WiUig-type reaction.
- conditions usually used for this Wittig-type reaction can be employed. In particular, it is preferable to carry out the reaction under basic conditions and further to carry out the reaction in an inert solvent.
- the reaction temperature is usually about 150 to 1200, and a suitable temperature is usually about -80 to +100.
- the amount of the base is usually about 0.1 to 20 equivalents, and preferably 1 to 10 equivalents, per 1 equivalent of the fluorinated lactone (2).
- the type of the base is determined in consideration of the acidity of hydrogen bonded to the carbon at the ⁇ -position of the phosphorus atom of the phosphonium salt (6) as a raw material of the phosphorane (3) and the stability of the generated phosphorane (3). Use the appropriate type of base.
- Such a base can be selected, for example, from the following bases.
- an ether solvent, a hydrocarbon solvent, a polar solvent, an aqueous solvent, an alcohol solvent, or a mixed solvent thereof is preferable.
- the amount of the inert solvent to be used is usually about 5 to 100 parts by weight, preferably 10 to 100 parts by weight, per 1 part by weight of the fluorinated lactose (2). Is preferred.
- Specific examples of the ether-based solvent, the hydrocarbon-based solvent, and the polar solvent are preferably the ether-based solvent, the hydrocarbon-based solvent, and the polar solvent described as specific examples in the description of the fluorination reaction.
- As the aqueous solvent water or a mixed solvent of water and an alcohol solvent is preferable.
- alcohol solvent methanol, ethanol, toluene, t-amyl alcohol and the like are preferable.
- Particularly preferred solvents include getyl ether, THF, 1,2-dimethoxetane, t-butyl methyl ether, toluene, and benzene.
- the obtained fluorinated prostaglandin derivative (1) can convert its Z to another Z if necessary.
- Z is a hydroxyl group
- esterification Z an ordinary method, for example, a method described in a companion book such as “New Experimental Chemistry Course 14 Synthesis and Reaction of Organic Compounds (11)” (Maruzen) can be adopted.
- esterification by condensation with alcohols or phenols esterification with 0-alkylating agent, esterification with alkenes and alkynes
- a method such as esterification with dialkyl sulfates or halogenated hydrocarbons is used.
- Trinor prostaglandin F 2 Isopropyl ester.
- N-methanesulfonyl- 1 6 (3-chlorophenoxy) 1 15-deoxy 1 15 1-fluoro-17,1 8 19,20-tetranorprostaglandin
- the physiological activity of the compounds of the present invention as compared to the native PGF 2 u have nearly equal or higher intraocular pressure activity, yet eye irritation and corneal, iris, the impact on the eye tissue of the conjunctiva, etc. It has been improved. In vivo, it is extremely resistant to degradation by metabolism such as hydrolysis and oxidation, and is very useful as a pharmaceutical because of its high corneal permeability and high intraocular absorption. Therefore, the medicament of the present invention is particularly effective as a therapeutic agent for glaucoma or ocular hypertension.
- the medicament for an eye disease of the present invention is used by topically administering a preparation containing the above-mentioned compound of the present invention as an active ingredient to the eye by a method such as eye dropping.
- a method such as eye dropping.
- the dosage form include eye drops such as eye drops and eye ointments, injections, and the like, and the compound of the present invention can be formulated using commonly used techniques.
- isotonic agents such as sodium chloride and concentrated glycerin
- buffering agents such as sodium phosphate and sodium acetate, polyoxyethylene sorbin monoester (hereinafter referred to as polysorbate 80)
- Surfactants such as polyoxyl stearate 40, polyoxyoxyethylene hydrogenated castor oil, stabilizing agents such as sodium citrate and sodium edetate, and preservatives such as benzalkonium chloride and paraben, as required.
- the pH can be in the range acceptable for ophthalmic preparations, but is preferably in the range of 4 to 8.
- the dose can be appropriately selected depending on the symptom, age, and dosage form.
- 0.01 to 5% (w / v), preferably 0.01 to 0.5% (wZv ) Can be applied once to several times a day.
- Examples 1 to 18 are synthesis examples of the fluorine-containing prostaglandin derivative of the present invention and an intermediate for synthesizing the same.
- Examples 16 to 20 are examples in which a fluorinated prostaglandin derivative represented by the formula (1) was obtained.
- Example 21 is an example of preparation of a pharmaceutical preparation of the present invention.
- Example 22 is an example in which the fluorinated prostaglandin derivative represented by the formula (1) was evaluated as a drug for ophthalmic diseases.
- THF refers to tetrahydrofuran.
- ⁇ NR (CDC1 3): ⁇ 1.5-2, 4 (m, 18H), 2.04 (s, 3H), 3.5-3.6 (m, 2H), 3.67 (s, 3H), 3.8-4.2 (m, 3H) , 4.55-4.71 (m, 1H), 5.04 (m, 1H), 5.37 (m, 2H).
- Example 7 7-[(1R, 2R, 3R, 5S) -1- [2-formyl-1-5-acetoxy-3- (2-tetrahydroviranyloxy)] cyclopentyl] hexene 5-ene synthesized in Example 3
- the title compound was synthesized in the same manner as in Example 4, Example 5, Example 6, Example 7, and Example 8 from methyl methacrylate and dimethyl 2-oxo-3- (3-trifluoromethyl) phenylpropylphosphonate.
- Example 11 53.3 g of the enone synthesized in 1 was dissolved in a mixed solvent of methylene chloride (250 ml) and methanol (500 ml), and cerium trichloride heptahydrate 16.8 was dissolved. 5 g were added. After cooling to 178 t :, add 3.41 g of sodium borohydride, stir for 2.5 hours, add 1N hydrochloric acid to adjust the pH to about 3, then concentrate, and concentrate ethyl acetate. And washed with saturated saline and a 3% aqueous solution of citric acid. After drying, the mixture was concentrated and purified by silica gel column chromatography (ethyl hexanoacetate 3/2) to obtain 26.2 g of the title compound.
- silica gel column chromatography ethyl hexanoacetate 3/2
- Example 3 7-[(1R, 2R, 3R, 5S)-[2-formyl-5-acetoxy-3- (2-tetrahydrobiranyloxy)] cyclopentyl] hexa synthesized in Example 3
- the title compound was synthesized in the same manner as in Examples 11 to 16 from methyl 5-enoate and dimethyl [3-phenoxy-12-oxopropyl] phosphonate.
- the enone synthesized in the same manner as in Example 11 was reduced to an allylic alcohol form, then hydrogenated in the presence of a palladium catalyst, and the obtained alcohol form was used in the reactions of Examples 12 and below.
- Compound A 1 6-(3,5-dichlorophenoxy) 1 15 -deoxy 1 15 -fluoro- 17,7,8,1 9,20-tetranorprostaglandin F 2u isopropyl ester (hereinafter referred to as Compound A)
- Compound A The following are typical formulation examples of ophthalmic solutions and eye ointments using
- Compound A 50 mg concentrated glycerin 250 mg polysorbate 800 500 mg sodium dihydrogen phosphate hydrate 20 mg sterile purified water
- the intraocular pressure decreased from 2 hours after instillation of Compound A, and a marked decrease in intraocular pressure was observed 6 hours after instillation. Also, the degree of intraocular pressure reduction was about 1.5 times 6 hours after instillation of Compound A compared to rattanobrost. This supports that the compound of the present invention has an intraocular pressure lowering action with excellent durability.
- test compound was instilled 10 times into the conjunctival sac of the right eye at 30 minute intervals. Anterior segment symptoms and anterior chamber symptoms were observed immediately before and 1, 2, and 4 hours after the last instillation, and corneal damage was observed 4 hours after the last instillation. In the left conjunctival sac, only a base containing no test compound was instilled.
- a scoring was performed according to the scoring criteria for eye disorders according to the modified Draize method shown below. [Scoring criteria for eye disorders]
- the mucous membrane is very light reddish, with slight dilation of the blood vessels on the face; 0.5
- Table 2 shows an example of the experimental results.
- Table 3 shows the results obtained when 0.1% (wZV) ophthalmic solution (reference formulation 1) of rayunoprost, which is known as a therapeutic agent for glaucoma, was instilled. Furthermore, in order to comprehensively evaluate the degree of disability of the anterior eye, a total value of each score was calculated and shown as a comprehensive evaluation.
- the prostaglandin derivative having a fluorine atom at the 15-position of the present invention is useful as an active ingredient of a drug.
- the medicament containing this compound as an active ingredient is particularly useful as a medicament for preventing or treating eye diseases.
- This drug is excellent as a drug for ophthalmic diseases that has high pharmacological action and low side effects.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT97940373T ATE221048T1 (de) | 1996-09-17 | 1997-09-12 | Fluorierte prostaglandinderivate und medikamente |
DE69714274T DE69714274T3 (de) | 1996-09-17 | 1997-09-12 | Fluorierte prostaglandinderivate und medikamente |
EP97940373A EP0930296B2 (en) | 1996-09-17 | 1997-09-12 | Fluorinated prostaglandin derivatives and medicines |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24515596 | 1996-09-17 | ||
JP8/245155 | 1996-09-17 | ||
JP8/346286 | 1996-12-25 | ||
JP8346286A JPH10182598A (ja) | 1996-12-25 | 1996-12-25 | 含フッ素プロスタグランジン誘導体の製造方法 |
JP410997 | 1997-01-13 | ||
JP9/4109 | 1997-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998012175A1 true WO1998012175A1 (fr) | 1998-03-26 |
Family
ID=27276117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/003236 WO1998012175A1 (fr) | 1996-09-17 | 1997-09-12 | Derives de prostaglandine fluores et medicaments |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0930296B2 (ja) |
AT (1) | ATE221048T1 (ja) |
DE (1) | DE69714274T3 (ja) |
WO (1) | WO1998012175A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850926A2 (en) * | 1996-12-26 | 1998-07-01 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US5977173A (en) * | 1997-09-09 | 1999-11-02 | Wos; John August | Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists |
US6048895A (en) * | 1997-09-09 | 2000-04-11 | The Procter & Gamble Company | Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists |
US6107338A (en) * | 1997-09-09 | 2000-08-22 | The Procter & Gamble Company | Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US8252945B2 (en) | 2005-04-13 | 2012-08-28 | Ube Industries, Ltd. | Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
WO2014144781A1 (en) | 2013-03-15 | 2014-09-18 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9006291B2 (en) | 2009-02-03 | 2015-04-14 | Pharma Patent Holding Inc. | Composition, method and kit for enhancing hair |
US9138438B2 (en) | 2005-03-31 | 2015-09-22 | Asahi Glass Company, Limited | Method for protecting a retinal neuronal cell |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US10112920B2 (en) | 2008-07-25 | 2018-10-30 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10174017B2 (en) | 2009-05-01 | 2019-01-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10472327B2 (en) | 2007-01-10 | 2019-11-12 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL134241A (en) * | 2000-01-27 | 2006-06-11 | Finetech Pharmaceutical Ltd | Process for the preparation of latanoprost |
IL143477A (en) | 2001-05-31 | 2009-07-20 | Finetech Pharmaceutical Ltd | Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives |
WO2002022131A1 (fr) * | 2000-09-13 | 2002-03-21 | Santen Pharmaceutical Co., Ltd. | Collyre |
US6476064B1 (en) * | 2001-06-13 | 2002-11-05 | Allergan, Inc. | Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents |
DE602004030245D1 (de) * | 2003-07-03 | 2011-01-05 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
CN103804338A (zh) * | 2006-02-07 | 2014-05-21 | 株式会社·R-技术上野 | 用于制备***素衍生物的方法 |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
CN108366984A (zh) | 2015-09-22 | 2018-08-03 | 灰色视觉公司 | 用于治疗眼部病症的化合物和组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03501025A (ja) * | 1988-09-06 | 1991-03-07 | フアーマシア・アンド・アツプジヨン・アー・ベー | 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体 |
JPH07165703A (ja) * | 1993-08-03 | 1995-06-27 | Alcon Lab Inc | 緑内障及び高眼圧治療用局所眼薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0770054A (ja) † | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
JP4248022B2 (ja) † | 1996-11-12 | 2009-04-02 | アルコン ラボラトリーズ,インコーポレイテッド | 眼圧降下剤としての15―フルオロプロスタグランジン |
JP3480549B2 (ja) * | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
WO1999012898A1 (en) * | 1997-09-09 | 1999-03-18 | The Procter & Gamble Company | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
US9259564B2 (en) † | 2009-01-22 | 2016-02-16 | Avent, Inc. | Enteral feeding assembly with lock assembly |
-
1997
- 1997-09-12 EP EP97940373A patent/EP0930296B2/en not_active Expired - Lifetime
- 1997-09-12 AT AT97940373T patent/ATE221048T1/de not_active IP Right Cessation
- 1997-09-12 DE DE69714274T patent/DE69714274T3/de not_active Expired - Lifetime
- 1997-09-12 WO PCT/JP1997/003236 patent/WO1998012175A1/ja active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03501025A (ja) * | 1988-09-06 | 1991-03-07 | フアーマシア・アンド・アツプジヨン・アー・ベー | 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体 |
JPH07165703A (ja) * | 1993-08-03 | 1995-06-27 | Alcon Lab Inc | 緑内障及び高眼圧治療用局所眼薬組成物 |
Non-Patent Citations (1)
Title |
---|
BIOORG. KHIM., Vol. 7, No. 3, (1981), BEZUGLOV V.V. et al., "Synthesis of Tritium-Labeled 15-Fluoro-15-Deoxyprostaglandins A2, B2 and F2Alpha", pages 448-454. * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850926A3 (en) * | 1996-12-26 | 1999-06-16 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
EP0850926A2 (en) * | 1996-12-26 | 1998-07-01 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US5977173A (en) * | 1997-09-09 | 1999-11-02 | Wos; John August | Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists |
US6048895A (en) * | 1997-09-09 | 2000-04-11 | The Procter & Gamble Company | Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists |
US6107338A (en) * | 1997-09-09 | 2000-08-22 | The Procter & Gamble Company | Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9675539B2 (en) | 2000-03-31 | 2017-06-13 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9138438B2 (en) | 2005-03-31 | 2015-09-22 | Asahi Glass Company, Limited | Method for protecting a retinal neuronal cell |
US8252945B2 (en) | 2005-04-13 | 2012-08-28 | Ube Industries, Ltd. | Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
US10472327B2 (en) | 2007-01-10 | 2019-11-12 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10899714B2 (en) | 2007-01-10 | 2021-01-26 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US10532993B2 (en) | 2008-07-25 | 2020-01-14 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US11021456B2 (en) | 2008-07-25 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10112920B2 (en) | 2008-07-25 | 2018-10-30 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US10882840B2 (en) | 2008-07-25 | 2021-01-05 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US9006291B2 (en) | 2009-02-03 | 2015-04-14 | Pharma Patent Holding Inc. | Composition, method and kit for enhancing hair |
US11618748B2 (en) | 2009-05-01 | 2023-04-04 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US11028081B2 (en) | 2009-05-01 | 2021-06-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10174017B2 (en) | 2009-05-01 | 2019-01-08 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10316029B2 (en) | 2009-05-01 | 2019-06-11 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US10654844B2 (en) | 2009-05-01 | 2020-05-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
EP3461484A1 (en) | 2013-03-15 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11185538B2 (en) | 2013-03-15 | 2021-11-30 | Aerie Pharmaceuticals, Inc. | Compositions for treating glaucoma or reducing intraocular pressure |
US10588901B2 (en) | 2013-03-15 | 2020-03-17 | Aerie Pharmaceuticals, Inc. | Combination therapy |
WO2014144781A1 (en) | 2013-03-15 | 2014-09-18 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP4335507A2 (en) | 2013-03-15 | 2024-03-13 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9415043B2 (en) | 2013-03-15 | 2016-08-16 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9993470B2 (en) | 2013-03-15 | 2018-06-12 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP3811943A1 (en) | 2013-03-15 | 2021-04-28 | Aerie Pharmaceuticals, Inc. | Compound for use in the treatment of ocular disorders |
US11020385B2 (en) | 2013-03-15 | 2021-06-01 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9931336B2 (en) | 2013-03-15 | 2018-04-03 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9849122B2 (en) | 2013-03-15 | 2017-12-26 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US10568878B2 (en) | 2013-03-15 | 2020-02-25 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US11197853B2 (en) | 2013-03-15 | 2021-12-14 | Aerie Pharmaceuticals, Inc. | Combination therapy |
EP4218759A2 (en) | 2013-03-15 | 2023-08-02 | Aerie Pharmaceuticals, Inc. | Combination therapy |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11590123B2 (en) | 2016-08-31 | 2023-02-28 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11707460B2 (en) | 2016-08-31 | 2023-07-25 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US11312700B2 (en) | 2017-03-31 | 2022-04-26 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US10858339B2 (en) | 2017-03-31 | 2020-12-08 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11891376B2 (en) | 2018-09-14 | 2024-02-06 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Also Published As
Publication number | Publication date |
---|---|
EP0930296A4 (en) | 1999-11-17 |
EP0930296B1 (en) | 2002-07-24 |
ATE221048T1 (de) | 2002-08-15 |
DE69714274T3 (de) | 2006-06-01 |
DE69714274D1 (de) | 2002-08-29 |
DE69714274T2 (de) | 2003-03-27 |
EP0930296B2 (en) | 2005-11-02 |
EP0930296A1 (en) | 1999-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998012175A1 (fr) | Derives de prostaglandine fluores et medicaments | |
JP3994074B2 (ja) | ジフルオロプロスタグランジン誘導体およびその用途 | |
US6344478B2 (en) | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension | |
EP0455264B1 (en) | Ocular hypotensive agents | |
USRE43372E1 (en) | C16 unsaturated FP-selective prostaglandins analogs | |
AU741014B2 (en) | Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists | |
JP2001522893A (ja) | 医薬としてのシクロペンタンヘプタン(エン)酸,2−ヘテロアリールアルケニル誘導体 | |
JP2001515885A (ja) | Fpアゴニストとして有用な、芳香族のあるc16〜c20が置換されたテトラヒドロプロスタグランジン類 | |
EP0366279A2 (en) | Ocular hypotensive agents | |
JPH10259179A (ja) | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 | |
HUT65913A (en) | Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives, pharmaceutical comp. cont. them and method to prepare them | |
JP4004109B2 (ja) | 含フッ素プロスタグランジン誘導体および医薬 | |
JP2007505110A (ja) | 医薬としてのシクロペンタンヘプタン(エン)酸,2−チオカルバモイルオキシおよびカルバモイルオキシ化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09147837 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997940373 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997940373 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997940373 Country of ref document: EP |